alent to the binding and activation domains ob- 
served in some eukaryotic transcriptional trans-acti- 
vators. Targeted mutagenesis of the putative activa- 
tion domain gave rise to Rev proteins that displayed 
a dominant negative phenotype. These mutant rev 
genes may have potential use in a novel gene ther- 
apy approach to AIDS treatment that has been re- 
ferred to as intracellular immunization. This possi- 
bility, which is being aggressively pursued by Dr. 
PUBLICATIONS 
CuUen's laboratory, is an example of the generaliza- 
tion that basic research in the biomedical sciences 
can lead to unexpected discoveries of direct medi- 
cal significance. 
Dr. CuUen is also Assistant Medical Research Pro- 
fessor in the Departments of Medicine and of Mi- 
crobiology and Immunology at Duke University 
Medical Center. 
Books and Chapters of Books 
Hakimi, J., CuUen, B.R. , Chizzonitte, R., Ju, G., Bailon, P., Tsien, W-H., Schumann, M., and Liu, CM. 1988. 
Use of recombinant DNA-derived proteins in a robotic screen for identifying cell surface receptor antago- 
nists. In Biology of Actinomycetes '88. Japan Scientific Societies Press, pp 189-194. 
Sadaie, M.R., Benaissa, Z.N., Wong-Staal, F., and CuUen, B.R. 1989. HIV-1 rev protein displays a trans-repres- 
sor role which inhibits virus replication. In Modern Approaches to New Vaccines Including Prevention of 
AIDS (Lerner, R., Ginsberg, H., Chanock, R., and Brown, F., Eds.). Cold Spring Harbor, NY: Cold Spring 
Harbor, pp 47-55. 
Articles 
Bohnlein, S. , Hauber, J. , and CuUen, B.R. 1989. Identification of a U5-specific sequence required for efficient 
polyadenylation within the human immunodeficiency virus long terminal repeat. J Virol 63:421-424. 
Cullen, B.R. 1988. Expression of a cloned human interleukin-2 cDNA is enhanced by the substitution of a 
heterologous mRNA leader region. DNA 7:645-650. 
Cullen, B.R. , and Greene, WC. 1989. Regulatory pathways governing HFV-l replication. Cell 58:423-426. 
Hauber, J., Bouvier, M., Malim, M.H., and Cullen, B.R. 1988. Phosphorylation of the rev gene product of 
human immunodeficiency virus type 1. J Virol 62:4801-4804. 
Hauber, J. , Malim, M.H., and Cullen, B.R. 1989. Mutational analysis of the conserved basic domain of human 
immunodeficiency virus tat protein. J Virol 63:1181-1187. 
Malim, M.H., Bohnlein, S., Hauber, J., and Cullen, B.R. 1989. Functional dissection of the HFV-l Rev trans-zc- 
tivat or— derivation of a fraws-dominant repressor of Rev fianction. Cell 58:205-214. 
Malim, M.H., Fenrick, R., Ballard, D.W, Hauber, J., Bohnlein, E., and Cullen, B.R. 1989. Functional character- 
ization of a complex protein-DNA-binding domain located within the human immunodeficiency virus type 
1 long terminal repeat leader region. /V?ro/ 63:3213-3219. 
Malim, M.H., Hauber, J., Fenrick, R., and Cullen, B.R. 1988. Immunodeficiency virus rev ?mns-activator mod- 
ulates the expression of the viral regulatory genes. Nature 335:181-183. 
Malim, M.H. , Hauber, J. , Le, S.-Y, Maizel, J.V, and Cullen, B.R. 1989. The HIV-1 rev rran^-activator acts 
through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 
338:254-257. 
Rimsky, L., Hauber, J., Dukovich, M., Malim, M.H., Langlois, A., Cullen, B.R., and Greene, WC. 1988. Func- 
tional replacement of the HIV-1 rev protein by the HTLV-1 rex protein. Nature 335:738-740. 
184 
